Nilutamide

You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.

Nilutamide
Systematic (IUPAC) name
5,5-dimethyl-3-[4-nitro-3-(trifluoromethyl)phenyl] imidazolidine-2,4-dione
Identifiers
CAS number	63612-50-0
ATC code	L02BB02
PubChem	4493
DrugBank	APRD00150
Chemical data
Formula	C12H10F3N3O4
Mol. mass	317.221 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	38.0 to 59.1 hours
Excretion	?
Therapeutic considerations
Pregnancy cat.	?
Legal status
Routes	?

WikiDoc Resources for Nilutamide
Articles
Most recent articles on Nilutamide Most cited articles on Nilutamide Review articles on Nilutamide Articles on Nilutamide in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Nilutamide Images of Nilutamide Photos of Nilutamide Podcasts & MP3s on Nilutamide Videos on Nilutamide
Evidence Based Medicine
Cochrane Collaboration on Nilutamide Bandolier on Nilutamide TRIP on Nilutamide
Clinical Trials
Ongoing Trials on Nilutamide at Clinical Trials.gov Trial results on Nilutamide Clinical Trials on Nilutamide at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Nilutamide NICE Guidance on Nilutamide NHS PRODIGY Guidance FDA on Nilutamide CDC on Nilutamide
Books
Books on Nilutamide
News
Nilutamide in the news Be alerted to news on Nilutamide News trends on Nilutamide
Commentary
Blogs on Nilutamide
Definitions
Definitions of Nilutamide
Patient Resources / Community
Patient resources on Nilutamide Discussion groups on Nilutamide Patient Handouts on Nilutamide Directions to Hospitals Treating Nilutamide Risk calculators and risk factors for Nilutamide
Healthcare Provider Resources
Symptoms of Nilutamide Causes & Risk Factors for Nilutamide Diagnostic studies for Nilutamide Treatment of Nilutamide
Continuing Medical Education (CME)
CME Programs on Nilutamide
International
Nilutamide en Espanol Nilutamide en Francais
Business
Nilutamide in the Marketplace Patents on Nilutamide
Experimental / Informatics
List of terms related to Nilutamide

Editor-In-Chief: Steven C. Campbell, M.D., Ph.D., Professor of Surgery, Residency Program Director, Section of Urologic Oncology, Glickman Urological and Kidney Institute, Cleveland Clinic. You can email Dr. Campbell by clicking here. Office phone: 216-444-5595.

Please Join in Editing This Page and Apply to be an Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Overview

Nilutamide is an antiandrogen medication used in the treatment of advanced stage prostate cancer. Nilutamide blocks the androgen receptor, preventing its interaction with testosterone. Because most prostate cancer cells rely on the stimulation of the androgen receptor for growth and survival, nilutamide can prolong life in men with prostate cancer. Nilutamide is marketed under the name Nilandron in the United States.

References

• Kassouf W, Tanguay S, Aprikian AG. Nilutamide as second line hormone therapy for prostate cancer after androgen ablation fails. J. Urol. 2003 May;169(5):1742-4. PMID 12686822

v • d • e WikiDoc Research Resources for Nilutamide
Articles on Nilutamide	Most recent articles on Nilutamide • Most cited articles on Nilutamide • Review articles on Nilutamide • Articles on Nilutamide in N Eng J Med, Lancet, BMJ
Media (Slides, Video, Images, MP3) on Nilutamide	Powerpoint slides on Nilutamide • Images of Nilutamide • Photos of Nilutamide • Podcasts & MP3s on Nilutamide • Videos on Nilutamide
Evidence Based Medicine Regarding Nilutamide	Cochrane Collaboration on Nilutamide • Bandolier on Nilutamide • TRIP on Nilutamide
Cost Effectiveness of Nilutamide	Cost Effectiveness of Nilutamide
Clinical Trials Involving Nilutamide	Ongoing Trials on Nilutamide at Clinical Trials.gov • Trial results on Nilutamide • Clinical Trials on Nilutamide at Google
Guidelines / Policies / Government Resources (FDA/CDC) Regarding Nilutamide	US National Guidelines Clearinghouse on Nilutamide • NICE Guidance on Nilutamide • NHS PRODIGY Guidance • FDA on Nilutamide • CDC on Nilutamide
Textbook Information on Nilutamide	Books and Textbook Information on Nilutamide
Pharmacology Resources on Nilutamide	Dosing of Nilutamide • Drug interactions with Nilutamide • Side effects of Nilutamide • Allergic reactions to Nilutamide • Overdose information on Nilutamide • Carcinogenicity information on Nilutamide • Nilutamide in pregnancy • Pharmacokinetics of Nilutamide •
Genetics, Pharmacogenomics, and Proteinomics of Nilutamide	Genetics of Nilutamide • Pharmacogenomics of Nilutamide • Proteomics of Nilutamide
Newstories on Nilutamide	Nilutamide in the news • Be alerted to news on Nilutamide • News trends on Nilutamide
Commentary on Nilutamide	Blogs on Nilutamide
Patient Resources on Nilutamide	Patient resources on Nilutamide • Discussion groups on Nilutamide • Patient Handouts on Nilutamide • Directions to Hospitals Treating Nilutamide • Risk calculators and risk factors for Nilutamide
Healthcare Provider Resources on Nilutamide	Symptoms of Nilutamide • Causes & Risk Factors for Nilutamide • Diagnostic studies for Nilutamide • Treatment of Nilutamide
Continuing Medical Education (CME) Programs on Nilutamide	CME Programs on Nilutamide
International Resources on Nilutamide	Nilutamide en Espanol • Nilutamide en Francais
Business Resources on Nilutamide	Nilutamide in the Marketplace • Patents on Nilutamide
Informatics Resources on Nilutamide	List of terms related to Nilutamide

v • d • e Sex hormones and related agents (primarily G03, also L02, H01C) - human endogenous in CAPS
Progestogens: (receptor)	PROGESTERONE,Dienogest, Desogestrel, Drospirenone, Dydrogesterone, Ethisterone, Etonogestrel, Ethynodiol diacetate, Gestodene, Gestonorone, Levonorgestrel, Lynestrenol, Medroxyprogesterone, Megestrol, Norelgestromin, Norethisterone, Norethynodrel, Norgestimate, Norgestrel, Norgestrienone, Tibolone Selective progesterone receptor modulator: Asoprisnil, CDB-4124 Antiprogestogen: Mifepristone
Androgens: (receptor)	TESTOSTERONE, Androstanolone, Fluoxymesterone, Mesterolone, Methyltestosterone, (see also anabolic steroids) Antiandrogens: Bicalutamide, Cyproterone, Dienogest, Flutamide, Nilutamide, Spironolactone
Estrogens: (receptor)	ESTRADIOL, ESTRIOL, ESTRONE, Chlorotrianisene, Dienestrol, Diethylstilbestrol, Ethinylestradiol, Fosfestrol, Mestranol, Polyestradiol phosphate Selective estrogen receptor modulator: Afimoxifene, Arzoxifene, Bazedoxifene, Clomifene, Fulvestrant, Lasofoxifene, Raloxifene, Tamoxifen, Toremifene Aromatase inhibitor: Aminogluthetimide, Anastrozole, Atamestane, Exemestane, Formestane, Letrozole, Vorozole
Gonadotropins: (FSHR/LHCGR)	ovulation stim.: Clomifene, Urofollitropin Antigonadotropins: Danazol, Gestrinone
GnRH: (receptor)	agonist: Buserelin, Goserelin, Histrelin, Leuprorelin, Nafarelin, Triptorelin antagonist: Abarelix, Cetrorelix, Ganirelix